Stanford Selected by NIH as Remdesivir Clinical Trial Site
A team of Stanford Department of Medicine scientists is partnering with the National Institutes of Health to evaluate the safety and efficacy of remdesivir as a treatment for COVID-19. Following a site visit on Friday, the university received approval to join 74 other research institutions around the globe in evaluating the novel antiviral drug.
In an announcement, Neera Ahuja, MD, Division Chief of Hospital Medicine and Medical Director of General Inpatient Medicine and the PI of the study, noted that Stanford’s selection as a clinical trial site resulted from an outstanding collaborative effort between Kari Nadeau, MD, PhD, Director of the Sean N. Parker Center for Allergy and Asthma Research and co-PI; Jasmine Noelle LaCoursiere of the Center for Clinical Research; Benjamin Pinsky, MD, PhD of the Clinical Virology Laboratory who developed the testing for the treatment; members of the pharmacy; and more. Drs. Jeff Chi, Nidhi Rohatgi, and Jessie Kittle are key investigators of this NIH study at Stanford.